Updated:
Nichi-Iko Pharmaceutical Co.
Nichi-Iko Pharmaceutical Co. is a other based in Toyama; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts...
Nichi-Iko Pharmaceutical Co.
General information
Firm type
other
Location
Region
Asia
Country
Japan
City
Toyama
Corporate office
Toyama, Japan
Frequently asked questions
What does Nichi-Iko Pharmaceutical Co. do?
Nichi-Iko is a Japanese pharmaceutical company focused on the development, manufacturing, and marketing of generic drugs. It supplies products to the Japanese healthcare system, aiming to provide cost-effective alternatives to brand-name medications. The company is known for oral disintegrating tablets and formulations that address swallowing difficulties.
Where is Nichi-Iko headquartered and does it have other offices?
The company is headquartered in Toyama, Japan. In late 2025 and early 2026, it relocated its Tokyo headquarters and Kudan office, indicating a consolidation or expansion of its Tokyo-area presence.
What recent regulatory approvals has Nichi-Iko received?
In April 2026, Nichi-Iko announced additional approval for palonosetron intravenous injection 0.75mg/2mL 'Nichi-Iko,' adding a new dosage and administration indication. In January 2026, it received expanded approval for rivaroxaban OD tablets 10mg/15mg for adult and pediatric venous thromboembolism treatment and recurrence prevention (per company press releases).
Does Nichi-Iko operate outside Japan?
Based on available sources, the company's operations appear concentrated in Japan. Its official website and press releases are in Japanese, and its recent office moves are within Tokyo. No international subsidiaries or geographic expansion plans have been publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: